BioSpace News Archive

Warning signs that preceded the current economic squeeze in the biopharma sector were not heeded by investors seeking rapid profits. Now, biotechs interested in making the leap to the public markets must get creative.

Bristol Myers Squibb announced Monday that Reblozyl is now approved as a first-line treatment for adults with anemia due to myelodysplastic syndromes who may require regular blood transfusions.

Data from the first-in-human trial showed that Eli Lilly’s muvalaplin is safe and can cut significant levels of lipoprotein(a), a risk factor for atherosclerosis and related cardiovascular diseases.

Lupin Pharmaceuticals’ recall of Tydemy birth control is the latest in a string of problems with India-based generic drug manufacturers.

The Biden administration on Tuesday released a much-anticipated list of the first 10 medicines included in Medicare’s Drug Price Negotiation Program under the Inflation Reduction Act.

The company’s investigational electric field therapy was unable to elicit significant survival benefits in patients with platinum-resistant ovarian cancer.

NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals, and Curadh MTR Inc. (Curadh), a global MTR focused clinical, research and advisory organization, today announced the signing of a strategic long term supply agreement for the therapeutic radioisotope non-carrier added (n.c.a.) actinium-225 (Ac-225).

$48.7 million in cash and cash equivalents at June 30, 2023, providing expected runway to advance Company’s development candidate (“DC”) through Phase I clinical development in healthy human volunteers and Duchenne muscular dystrophy patients

Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing allogeneic cell therapies and biomaterial products, announced today a multi-year Research Collaboration Services Agreement with Regeneron Pharmaceuticals, Inc. (Regeneron) to support the research of Regeneron’s allogeneic cell therapy candidates.

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) today announced the publication of a manuscript reporting on the ability of Shuttle’s lead Histone deacetylase 6 (HDAC6) inhibitor drug candidate (SP-2-225) to stimulate the innate immune system following radiation therapy.